Despite of promising results in emerging targeted medications including BCL-2 inhibitor venetoclax and Bruton tyrosine kinase (BTK) inhibitors represented by ibrutinib and zanubrutinib [8–11], it cannot be neglected that the high-cost treatment and accompanied severe adverse events contributed to a heavy global burden to CLL patients. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.